Sequential Hormonal Regimen for Cycle Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing estrogenic/progestogenic contraceptive regimens face challenges in reducing daily estrogen exposure while maintaining contraceptive efficacy and cycle control, as lower estrogen doses often lead to increased breakthrough bleeding and spotting, and extended regimens suffer from poor initial cycle control.
Innovation Solution
A method involving sequential administration of a progestin and estrogen combination for 22-26 days, followed by estrogen alone for 2-3 days, with an optional placebo phase, to minimize daily estrogen exposure and ensure predictable withdrawal bleeding, thereby maintaining contraceptive efficacy and cycle control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If the estrogenic component dose is reduced to minimize daily estrogen exposure, then the risk of acute thrombosis is reduced, but breakthrough bleeding or spotting increases
Solution Approach 1:
The patent divides the menstrual cycle into distinct phases with different hormonal compositions: Phase I (days 1-6) uses estrogen-only at low dose, Phase II (days 7-26) uses combination therapy with progestin and estrogen, and Phase III (days 27-28) uses placebo. This segmentation allows minimal estrogen exposure during the follicular phase while providing adequate estrogen coverage during the luteal phase when breakthrough bleeding risk is highest, thus resolving the contradiction between thrombosis risk reduction and bleeding control.
Solution Approach 2:
The patent employs parameter changes by adjusting the estrogen dose according to the phase of the menstrual cycle. During Phase I, a low estrogen dose (5-20 mcg ethinyl estradiol equivalent) is used to minimize thrombosis risk, while during Phase II, the same low dose is maintained but combined with progestin to prevent breakthrough bleeding. This dynamic parameter adjustment resolves the contradiction by adapting the hormonal regimen to the physiological needs of different cycle phases.
2Reliability
If extended estrogen/progestin administration is used to provide continuous coverage, then contraceptive efficacy is maintained, but initial cycle control becomes poor
Solution Approach 1:
The patent applies preliminary action by administering a low-dose estrogen-only regimen during Phase I (days 1-6) before introducing the combination therapy in Phase II. This preliminary estrogen exposure prepares the endometrium and establishes initial cycle control, reducing breakthrough bleeding during the critical early days. When combination therapy is started on day 7, the endometrium is already stabilized, preventing the poor initial cycle control that would otherwise occur with abrupt combination therapy initiation.
Solution Approach 2:
The patent uses periodic action by structuring the regimen into distinct phases that repeat cyclically: Phase I (estrogen-only) for days 1-6, Phase II (combination) for days 7-26, and Phase III (placebo) for days 27-28. This periodic structure provides predictable withdrawal bleeding during Phase III while maintaining continuous contraceptive coverage during Phases I and II, thus maintaining both reliability and cycle control.
3Productivity
If extended regimen is used to reduce frequency of treatments, then number of menstrual cycles per year is reduced, but user becomes functionally amenorrheic leading to pregnancy uncertainty
Solution Approach 1:
The patent incorporates a periodic placebo phase (Phase III, days 27-28) that occurs twice yearly in extended regimens. During this phase, hormones are withdrawn to produce predictable withdrawal bleeding, providing users with periodic reassurance of non-pregnancy status. This periodic action maintains the benefits of extended regimens (reduced treatment frequency) while preserving the psychological reassurance function through scheduled bleeding events.
Data Source
AI summary
A method of contraception that provides for sequentially administering to a female of child bearing age: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 22 to about 26 days; (b) a second composition containing an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 2 to about 3 days and an optional third composition that is a placebo provided that (i) if estrogen administration is continuous then the first composition is administered for 25 to 26 days, the second composition is administered for 2 to 3 days and no third composition is administered and (ii) if estrogen administration is not continuous then the first composition is administered for 22 to 24 days, the second composition is administered for 2 to 3 days and the third composition is administered for 1 to 4 days. The total cycle length is 28 days, with the first composition administered on day 1 of the menstrual cycle, defined as the first day of menstrual bleeding, or on the first Sunday after the first day of the menstrual cycle.